Methods for reduction of pressure effects of cardiac tricuspid valve regurgitation

• US 7,159,593 B2
• Filed: 04/17/2003
• Issued: 01/09/2007
• Est. Priority Date: 04/17/2003
• Status: Expired due to Term

• Current Assignee: 3F Therapeutics Incorporated (Medtronic Plc)
• Original Assignee: 3F Therapeutics Incorporated (Medtronic Plc)
• Inventors: McCarthy, Patrick M., Quijano, Rodolfo C. Quijano
• Primary Examiner(s): BARRETT, THOMAS C
• Application Number:
  US10/418,663
• Publication Number:
  US 20040206363A1
• Time in Patent Office: 1,363 Days
• Field of Search: 128/898, 623/1.24
• US Class Current: 128/898
• CPC Class Codes: A61F 2/2418 Scaffolds therefor, e.g. support stents
• CPC Class Codes: A61F 2/2475 Venous valves
• CPC Class Codes: A61F 2220/0008 Fixation appliances for connecting prostheses to the body
• CPC Class Codes: A61F 2220/0016 with sharp anchoring protrusions, e.g. barbs, pins, spikes
• CPC Class Codes: A61F 2230/0054 V-shaped
• CPC Class Codes: A61F 2250/0062 Kits of prosthetic parts to be assembled in various combinations for forming different prostheses

Abstract

A method of protecting an upper body and a lower body of a patient from high venous pressures comprising implanting a first stented valve at the superior vena cava and a second stented valve at the inferior vena cava, wherein the first and second valves are configured to permit blood flow towards a right atrium of the patient and prevent blood flow in an opposite direction.

Claims

1. A method of protecting an upper body and a lower body of a patient from high venous pressures comprising implanting a first pericardium tissue valve at a superior vena cava and a second pericardium tissue valve at an inferior vena cava, wherein said first and second valves are configured to permit blood flow towards a right atrium of the patient and prevent blood flow in an opposite direction wherein the first valve is connected to the second valve.

2. The method of claim 1, wherein the first valve or the second valve is a stented valve.

3. The method of claim 1, wherein the step of implanting the first valve at the superior vena cava is by endoluminally delivering said valve through an incision at a blood vessel selected from a group consisting of a jugular vein, a femoral vein, and a subclavian vein.

4. The method of claim 1, wherein the step of implanting the second valve at the inferior vena cava is by endoluminally delivering said valve through an incision at a blood vessel selected from a group consisting of a jugular vein, a femoral vein, and a subclavian vein.

5. The method of claim 1, wherein the step of implanting further comprises first implanting the second pericardium tissue valve at the inferior vena cava followed by implanting the first pericardium tissue valve at the superior vena cava.

6. The method of claim 1, wherein the first pericardium tissue valve and the second pericardium tissue valve are secured to a support structure, wherein said support structure is collapsibly expandable.

7. The method of claim 6, wherein the step of implanting the first or the second valve further comprises passing said support structure through a blood vessel with the support structure in the collapsed position, expanding said support structure at a desired valve location;

and securing the tissue valve and the support structure to said desired valve location with the support structure in the expanded shape.

8. The method of claim 6, wherein said support structure is self-expandable.

9. The method of claim 6, wherein said support structure is expandable by positioning an inflatable balloon within said support structure and inflating said balloon.

10. The method of claim 6, wherein said support structure is made of a shape-memory material having a first shape transition temperature of between about 30°

C. and 45°

C. and a second shape transition temperature of about 5°

C. and −

10°

C., said support structure being collapsibly deformed to below the second shape transition temperature during delivery and expanded after delivery in place upon reaching the first shape transition temperature.

11. The method of claim 6, wherein said support structure is made of a material selected from the group consisting of stainless steel, Nitinol, and plastics.

12. The method of claim 6, wherein said support structure is coated with a therapeutic agent.

13. The method of claim 12, wherein said therapeutic agent is selected from the group consisting of anticoagulants, antithrombogenic agents, anti-proliferative agents, anti-inflammatory agents, antibiotics, stem cells, growth factors, angiogenesis agents, anti-angiogenesis agents, and statins.

14. The method of claim 1, wherein either the first or second pericardium tissue valve includes at least one valve leaflet.

15. The method of claim 6, wherein said support structure further comprises means for anchoring said support structure onto surrounding tissue of either the superior vena cava or the inferior vena cava.

16. The method of claim 6 wherein said support structure comprises a stent.

17. The method of claim 1, wherein the pericardium is selected from the group consisting of a bovine pericardium, an equine pericardium, a porcine pericardium, and an ovine pericardium.

18. The method of claim 1, wherein said first and second pericardium tissue valves are chemically treated with a chemical treating agent selected from the group consisting of glutaraldehyde, formaldehyde, dialdehyde starch, epoxy compounds, genipin, and mixture thereof.

19. The method of claim 1, wherein said first pericardium tissue valve is implanted at the superior vena cava above the right atrial junction but below the azygos vein.

20. The method of claim 1, wherein said second pericardium tissue valve is implanted at the inferior vena cava below the right atrium but above the hepatic veins.